-

$undefined

N/A

(N/A)

Insmed Incorporated NASDAQ:INSM Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. .

Location: 700 US Highway 202/206, New Jersey, 08807-1704, US | Website: www.insmed.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.4B

Cash

1.247B

Avg Qtr Burn

-143.5M

Short % of Float

7.61%

Insider Ownership

0.95%

Institutional Own.

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARIKAYCE (Amikacin Liposome Inhalation Suspension) Details Mycobacterium avium complex lung disease, Nontuberculous mycobacterial lung disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib (DPP1 inhibitor) Details Non-Cystic Fibrosis Bronchiectasis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary hypertension, Interstitial lung disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib (DPP1 inhibitor) Details Chronic rhinosinusitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPIP (Treprostinil Palmitil Inhalation Powder) Details Pulmonary arterial hypertension	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brensocatib (DPP1 inhibitor) Details Cystic fibrosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.